Clinical trialNCT06052293CompletedPhase 1Interventional

Phase 1 Study to Assess Safety and Efficacy of ANG003

SponsorAnagram Therapeutics, Inc.Enrollment57Exocrine Pancreatic Insufficiency

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Randomized, parallel, active-treatment Phase 1 study of a single dose of orally administered ANG003 with a test meal in adult subjects with cystic fibrosis-related exocrine pancreatic insufficiency. The study's overall objectives are to evaluate the safety, tolerability and effect of four dose levels of ANG003.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Meghana Sathe, MD
University of Texas
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Long Beach Memorial Medical Center
Long Beach, California, United States
National Jewish Health
Denver, Colorado, United States
Norton Children'S Research Institute Affiliated With University of Louisville School of Medicine
Louisville, Kentucky, United States
Boston Children'S Hospital
Boston, Massachusetts, United States
Massachusetts General Hospital,
Boston, Massachusetts, United States
University of Michigan Medical Center
Ann Arbor, Michigan, United States
Harper University Hospital / Wayne State University
Detroit, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Albany Medical College
Albany, New York, United States
New York Medical College at Westchester Medical Center
Valhalla, New York, United States
Akron Childrens Hospital
Akron, Ohio, United States
University of Cincinnati
Cincinnati, Ohio, United States
University Hospitals of Cleveland Medical Center
Cleveland, Ohio, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States
Upmc Children'S Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ANG003

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Aug 2023
Primary completion: 8 Jul 2024
Completion: 8 Jul 2024
Last update posted: 27 Apr 2026
Registered enrollment: 57
Registry id: NCT06052293

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.